Earnings Feed
Start Free
Akari Therapeutics Plc·4

Mar 10, 5:00 PM ET

Patel Samir Rashmikant 4

4 · Akari Therapeutics Plc · Filed Mar 10, 2025

Insider Transaction Report

Form 4
Period: 2025-03-06
Akari Therapeutics PlcAKTX
Patel Samir Rashmikant
Director
Transactions
  • Award

    Series A Warrants (Right to Buy)

    2025-03-06$1.12/sh+406,250$455,000→ 406,250 total(indirect: By LLC)
    Exercise: $0.87From: 2025-03-06Exp: 2026-03-06→ American Depositary Shares representing Ordinary Shares (406,250 underlying)
  • Award

    Series B Warrants (Right to Buy)

    2025-03-06$1.12/sh+406,250$455,000→ 406,250 total(indirect: By LLC)
    Exercise: $0.87From: 2025-03-06Exp: 2030-03-06→ American Depositary Shares representing Ordinary Shares (406,250 underlying)
  • Award

    American Depositary Shares representing Ordinary Shares

    2025-03-06$1.12/sh+406,250$455,000→ 3,031,005 total(indirect: By LLC)
Holdings

  • American Depositary Shares representing Ordinary Shares

    45,698
Footnotes (2)
  • [F1]Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
  • [F2]On March 6, 2025, the Reporting Person acquired 406,250 ADS and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

Documents

2 files